Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
| Title: | Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. |
|---|---|
| Authors: | Fendler A; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Equal contribution.; Au L; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Equal contribution.; Shepherd STC; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Equal contribution.; Byrne F; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Cerrone M; Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Department of Infectious Disease, Imperial College London, W12 0NN, UK.; Boos LA; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Rzeniewicz K; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Gordon W; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Shum B; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Gerard CL; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Ward B; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Xie W; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Schmitt AM; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Joharatnam-Hogan N; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Cornish GH; Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Pule M; Research Department of Haematology at University College London Cancer Institute, WC1E 6DD, London, UK.; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.; Mekkaoui L; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.; Ng KW; Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Carlyle E; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Edmonds K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Del Rosario L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Sarker S; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Lingard K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Mangwende M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Holt L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Ahmod H; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Stone R; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.; Gomes C; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.; Flynn HR; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.; Agua-Doce A; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.; Hobson P; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.; Caidan S; Safety, Health & Sustainability, The Francis Crick Institute, London, NW1 1AT, UK.; Howell M; High Throughput Screening Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Wu M; High Throughput Screening Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Goldstone R; Advanced Sequencing Facility, The Francis Crick Institute, London, NW1 1AT, UK.; Crawford M; Advanced Sequencing Facility, The Francis Crick Institute, London, NW1 1AT, UK.; Cubitt L; Advanced Sequencing Facility, The Francis Crick Institute, London, NW1 1AT, UK.; Patel H; Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.; Gavrielides M; Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.; Nye E; Experimental Histopathology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Snijders AP; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.; MacRae JI; Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.; Nicod J; Advanced Sequencing Facility, The Francis Crick Institute, London, NW1 1AT, UK.; Gronthoud F; Department of Pathology, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK.; Shea RL; Department of Pathology, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK.; Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, SW7 3RP, UK.; Messiou C; Department of Radiology, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Cunningham D; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey SM2 5PT.; Chau I; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey SM2 5PT.; Starling N; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey SM2 5PT.; Turner N; Breast Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Welsh L; Neuro-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; van As N; Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Jones RL; Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, SW3 6JJ, UK.; Droney J; Palliative Medicine, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Banerjee S; Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Tatham KC; Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Jhanji S; Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; O'Brien M; Lung Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Curtis O; Lung Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Harrington K; Head and Neck, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Targeted Therapy Team, The Institute of Cancer Research, London, SW7 3RP, UK.; Bhide S; Head and Neck, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Bazin J; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Robinson A; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Stephenson C; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Slattery T; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Khan Y; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Tippu Z; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Leslie I; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Gennatas S; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Department of Medical Oncology, 14th Floor, Great Maze Pond Road, Tower Wing, Guy's Hospital, London SE1 9RY, UK.; Okines A; Breast Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Reid A; Uro-oncology unit, The Royal Marsden NHS Foundation Trust, Surrey, SM2 5PT.; Young K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Furness AJS; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Pickering L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Gandhi S; Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG.; Gamblin S; Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; University College London Cancer Institute, London WC1E 6DD, UK.; Nicholson E; Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Kumar S; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey SM2 5PT.; Yousaf N; Lung Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Wilkinson KA; Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Wellcome Center for Infectious Disease Research in Africa, University Cape Town, Observatory 7925, Republic of South Africa.; Swerdlow A; Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, London, SW7 3RP, UK.; Harvey R; Worldwide Influenza Centre, The Francis Crick Institute, London, NW1 1AT, UK.; Kassiotis G; Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Larkin J; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.; Wilkinson RJ; Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Department of Infectious Disease, Imperial College London, W12 0NN, UK.; Wellcome Center for Infectious Disease Research in Africa, University Cape Town, Observatory 7925, Republic of South Africa.; Turajlic S; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK. |
| Source: | Research square [Res Sq] 2021 Sep 20. Date of Electronic Publication: 2021 Sep 20. |
| Publication Type: | Preprint; Journal Article |
| Language: | English |
| Journal Info: | Country of Publication: United States NLM ID: 101768035 Publication Model: Electronic Cited Medium: Internet ISSN: 2693-5015 (Electronic) Linking ISSN: 26935015 NLM ISO Abbreviation: Res Sq Subsets: PubMed not MEDLINE |
| Abstract: | Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2-positive, 94 were symptomatic and 2 patients died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies, 82% had neutralizing antibodies against WT, whereas neutralizing antibody titers (NAbT) against the Alpha, Beta, and Delta variants were substantially reduced. Whereas S1-reactive antibody levels decreased in 13% of patients, NAbT remained stable up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment-specific, but presented compensatory cellular responses, further supported by clinical. Overall, these findings advance the understanding of the nature and duration of immune response to SARS-CoV-2 in patients with cancer. |
| Comments: | Update in: Nat Cancer. 2021 Dec;2(12):1321-1337. doi: 10.1038/s43018-021-00275-9.. (PMID: 35121900) |
| References: | Cell Rep. 2021 Feb 9;34(6):108728. (PMID: 33516277); Cell Rep. 2020 Jun 30;31(13):107827. (PMID: 32610128); Cancer Cell. 2021 Feb 8;39(2):257-275.e6. (PMID: 33476581); Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463); Lancet Infect Dis. 2020 Aug;20(8):e192-e197. (PMID: 32539990); JAMA Intern Med. 2021 May 1;181(5):709-711. (PMID: 33492361); Immunology. 2010 May;130(1):92-102. (PMID: 20113370); Nat Cancer. 2021 Apr;2(4):392-399. (PMID: 34661163); Ann Oncol. 2021 Jan;32(1):113-119. (PMID: 33098994); J Virol. 2010 Sep;84(18):9318-25. (PMID: 20610717); Nat Med. 2020 Sep;26(9):1428-1434. (PMID: 32661393); Clin Infect Dis. 2021 Nov 2;73(9):e3130-e3132. (PMID: 33035306); Nature. 2020 Aug;584(7821):457-462. (PMID: 32668444); Nat Med. 2021 Feb;27(2):270-278. (PMID: 33335323); Nat Med. 2021 Jul;27(7):1280-1289. (PMID: 34017137); Cell. 2020 Oct 1;183(1):158-168.e14. (PMID: 32979941); Nature. 2020 Oct;586(7830):509-515. (PMID: 32967005); Lancet. 2020 Jun 20;395(10241):1919-1926. (PMID: 32473682); Nature. 2020 Oct;586(7830):594-599. (PMID: 32998157); Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127); Eur J Cancer. 2020 Nov;139:43-50. (PMID: 32971510); Genome Med. 2021 Feb 9;13(1):21. (PMID: 33563320); Cell Rep Med. 2021 Jul 20;2(7):100355. (PMID: 34230917); Ann Oncol. 2021 Jun;32(6):787-800. (PMID: 33746047); Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815); Ther Adv Med Oncol. 2020 Oct 23;12:1758835920971147. (PMID: 33178336); Lancet. 2020 Jun 20;395(10241):1907-1918. (PMID: 32473681); Nat Microbiol. 2020 Dec;5(12):1598-1607. (PMID: 33106674); Elife. 2021 Jul 29;10:. (PMID: 34323691); Sci Immunol. 2020 Jun 26;5(48):. (PMID: 32591408); Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662); Nat Biotechnol. 2020 Mar;38(3):276-278. (PMID: 32055031); Nat Biotechnol. 2020 Aug;38(8):927-931. (PMID: 32555528); Nat Med. 2021 Nov;27(11):1990-2001. (PMID: 34522051); Eur J Cancer. 2020 Sep;136:99-106. (PMID: 32659475); Science. 2020 Oct 2;370(6512):89-94. (PMID: 32753554); Nature. 2021 Mar;591(7851):639-644. (PMID: 33461210); Lancet Oncol. 2020 Oct;21(10):1309-1316. (PMID: 32853557); Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089); Science. 2021 Feb 5;371(6529):. (PMID: 33408181); Nat Biotechnol. 2017 Apr 11;35(4):316-319. (PMID: 28398311); Lancet Oncol. 2020 Jul;21(7):914-922. (PMID: 32539942); Nat Med. 2020 Aug;26(8):1218-1223. (PMID: 32581323); PLoS Biol. 2021 Feb 25;19(2):e3001091. (PMID: 33630831); Cell. 2020 Oct 1;183(1):4-10. (PMID: 32979319); Immunity. 2019 May 21;50(5):1132-1148. (PMID: 31117010); Vaccine. 2021 Jul 22;39(32):4423-4428. (PMID: 34210573); J Hematol Oncol. 2020 Oct 8;13(1):133. (PMID: 33032660); Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6. (PMID: 33975009); Nature. 2021 Jul;595(7867):426-431. (PMID: 34126625) |
| Grant Information: | U01 CA247439 United States CA NCI NIH HHS; FC001002 United Kingdom WT_ Wellcome Trust; FC001078 United Kingdom WT_ Wellcome Trust; FC001169 United Kingdom WT_ Wellcome Trust; FC001099 United Kingdom WT_ Wellcome Trust; FC001218 United Kingdom WT_ Wellcome Trust; FC001988 United Kingdom WT_ Wellcome Trust; FC001030 United Kingdom WT_ Wellcome Trust |
| Entry Date(s): | Date Created: 20210928 Latest Revision: 20250530 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8475970 |
| DOI: | 10.21203/rs.3.rs-916427/v1 |
| PMID: | 34580668 |
| Database: | MEDLINE |
Preprint; Journal Article